Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$290.52 +4.1%	$281.37	$253.30 ▼ $346.85	$150.13B	0.49	2.83 million shs	3.50 million shs
GILD Gilead Sciences	$111.73 +0.8%	$106.65	$66.01 ▼ $119.96	$137.91B	0.29	7.66 million shs	7.68 million shs
MRNA Moderna	$28.69 +4.0%	$26.52	$23.15 ▼ $129.39	$10.67B	1.85	8.59 million shs	14.53 million shs
PFE Pfizer	$25.03 +3.3%	$23.56	$20.92 ▼ $31.54	$137.81B	0.58	41.35 million shs	59.11 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	+4.05%	+4.70%	+1.22%	-4.97%	-6.59%
GILD Gilead Sciences	+0.78%	+4.23%	+1.25%	-0.14%	+62.78%
MRNA Moderna	+3.99%	+7.05%	+8.02%	+3.50%	-75.26%
PFE Pfizer	+3.13%	+2.98%	+6.69%	+1.21%	-11.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.2403 of 5 stars	2.2	2.0	3.3	3.9	3.3	2.5	0.6
GILD Gilead Sciences	4.8376 of 5 stars	1.4	3.0	4.2	4.1	4.0	2.5	3.1
MRNA Moderna	4.3613 of 5 stars	4.0	2.0	0.0	4.6	1.3	2.5	0.6
PFE Pfizer	4.8773 of 5 stars	2.3	3.0	4.2	4.3	2.8	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.35	Hold	$307.82	5.95% Upside
GILD Gilead Sciences	2.78	Moderate Buy	$110.55	-1.06% Downside
MRNA Moderna	2.04	Hold	$46.61	62.46% Upside
PFE Pfizer	2.53	Moderate Buy	$29.17	16.53% Upside

Current Analyst Ratings Breakdown

Latest PFE, AMGN, GILD, and MRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$328.00
6/24/2025	AMGN Amgen	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/24/2025	AMGN Amgen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$305.00
6/2/2025	MRNA Moderna	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
5/22/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$33.00 ➝ $26.00
5/21/2025	GILD Gilead Sciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/20/2025	AMGN Amgen	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$288.00
5/16/2025	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$329.00 ➝ $328.00
5/8/2025	AMGN Amgen	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/7/2025	AMGN Amgen	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$235.00 ➝ $280.00
5/2/2025	AMGN Amgen	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$319.00 ➝ $315.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	4.67	$31.61 per share	9.19	$10.93 per share	26.58
GILD Gilead Sciences	$28.75B	4.83	$6.92 per share	16.14	$15.44 per share	7.24
MRNA Moderna	$3.24B	3.43	N/A	N/A	$28.33 per share	1.01
PFE Pfizer	$63.63B	2.24	$4.51 per share	5.55	$15.62 per share	1.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$10.96	26.51	13.58	2.53	17.39%	176.11%	12.39%	8/5/2025 (Estimated)
GILD Gilead Sciences	$480M	$4.75	23.52	13.78	0.72	20.76%	51.93%	17.40%	8/6/2025 (Estimated)
MRNA Moderna	-$3.56B	-$8.73	N/A	N/A	N/A	-105.67%	-28.69%	-21.94%	7/30/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	18.14	8.26	0.88	12.62%	20.33%	8.53%	8/5/2025 (Estimated)

Latest PFE, AMGN, GILD, and MRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	Q1 2025	AMGN Amgen	$4.18	$4.90	+$0.72	$3.20	$8.05 billion	$8.15 billion
5/1/2025	Q1 2025	MRNA Moderna	-$2.92	-$2.52	+$0.40	-$2.52	$130.35 million	$108.00 million
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/24/2025	Q1 2025	GILD Gilead Sciences	$1.77	$1.81	+$0.04	$1.04	$6.77 billion	$6.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.28%	N/A	86.86%	14 Years
GILD Gilead Sciences	$3.16	2.83%	N/A	66.53%	10 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.87%	N/A	124.64%	16 Years

Latest PFE, AMGN, GILD, and MRNA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
4/22/2025	GILD Gilead Sciences	quarterly	$0.79	3%	6/13/2025	6/13/2025	6/27/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	8.70	1.17	0.88
GILD Gilead Sciences	1.16	1.37	1.23
MRNA Moderna	N/A	4.22	4.14
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
GILD Gilead Sciences	83.67%
MRNA Moderna	75.33%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.69%
GILD Gilead Sciences	0.27%
MRNA Moderna	11.00%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	28,000	537.71 million	534.00 million	Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable
MRNA Moderna	5,800	386.74 million	344.20 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

PFE, AMGN, GILD, and MRNA Headlines

Recent News About These Companies

Allspring Global Investments Holdings LLC Grows Position in Pfizer Inc. (NYSE:PFE)

2 hours ago | marketbeat.com

Pfizer scientist subpoenaed over claims COVID vax testing was ‘deliberately’ slowed before 2020 election

July 1 at 4:52 PM | msn.com

Pfizer (NYSE:PFE) Trading 3.3% Higher - What's Next?

July 1 at 3:40 PM | marketbeat.com

Pfizer ends phase 2 trial for lymphoma drug from Trillium acquisition

July 1 at 3:16 PM | seekingalpha.com

Cannabis Lighting Market Report 2025-2030 | Share Analysis, Industry Trends & Statistics, Growth Forecasts - Pfizer Ventures into Cannabis with $6.7 Billion Deal, Boosting Industry Growth

July 1 at 11:06 AM | globenewswire.com

Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth

July 1 at 10:36 AM | zacks.com

Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

July 1 at 10:01 AM | zacks.com

Sumitomo Mitsui DS Asset Management Company Ltd Has $19.82 Million Holdings in Pfizer Inc. (NYSE:PFE)

July 1 at 8:38 AM | marketbeat.com

BLB&B Advisors LLC Sells 25,375 Shares of Pfizer Inc. (NYSE:PFE)

July 1 at 8:09 AM | marketbeat.com

Alta Advisers Ltd Buys 13,100 Shares of Pfizer Inc. (NYSE:PFE)

July 1 at 7:05 AM | marketbeat.com

Hixon Zuercher LLC Acquires 14,753 Shares of Pfizer Inc. (NYSE:PFE)

July 1 at 6:47 AM | marketbeat.com

326,865 Shares in Pfizer Inc. (NYSE:PFE) Purchased by CHURCHILL MANAGEMENT Corp

July 1 at 6:30 AM | marketbeat.com

Pfizer (NYSE:PFE) Expands Collaboration With XtalPi To Enhance Drug Discovery Platform

July 1 at 4:42 AM | finance.yahoo.com

US House committee subpoenas former Pfizer executive over alleged COVID vaccine delay

June 30 at 4:52 PM | investing.com

House committee subpoenas Pfizer executive in probe of alleged COVID vaccine delay, CNN reports

June 30 at 4:01 PM | reuters.com

Pfizer’s Promising Phase 3 Study on Prostate Cancer Treatment: A Potential Game Changer

June 30 at 12:15 PM | tipranks.com

Pfizer’s Sayana Press Study: Optimizing Drug Delivery for Better Outcomes

June 30 at 12:15 PM | tipranks.com

Essex LLC Cuts Stock Holdings in Pfizer Inc. (NYSE:PFE)

June 30 at 9:04 AM | marketbeat.com

First Fiduciary Investment Counsel Inc. Buys 40,783 Shares of Pfizer Inc. (NYSE:PFE)

June 30 at 8:40 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Acquired by Argent Advisors Inc.

June 30 at 7:58 AM | marketbeat.com

New York State Teachers Retirement System Sells 142,670 Shares of Pfizer Inc. (NYSE:PFE)

June 30 at 6:41 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFE, AMGN, GILD, and MRNA Company Descriptions

Amgen NASDAQ:AMGN

$290.52 +11.31 (+4.05%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$290.35 -0.17 (-0.06%)

As of 06:11 AM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gilead Sciences NASDAQ:GILD

$111.73 +0.86 (+0.78%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$112.06 +0.33 (+0.30%)

As of 06:11 AM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Moderna NASDAQ:MRNA

$28.69 +1.10 (+3.99%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$28.98 +0.29 (+0.99%)

As of 06:14 AM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pfizer NYSE:PFE

$25.03 +0.79 (+3.26%)

Closing price 07/1/2025 03:59 PM Eastern

Extended Trading

$25.18 +0.15 (+0.62%)

As of 06:14 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time